By John Vandermosten, CFA
NASDAQ:NOVN
READ THE FULL NOVN RESEARCH REPORT
1Q:23 Financial and Operational Results
On May 15th, 2023, Novan Inc. (NASDAQ:NOVN) reported 1Q:23 financial and operational results in a press release and in the filing of Form 10-Q. A conference call and webcast were subsequently held to update investors on recent developments. The call highlighted the performance of the EPI Health assets and efforts related to SB206s New Drug Application (NDA) which has been assigned a target action date of January 25th, 2024. Novan is increasingly focused on potential funding or strategic arrangements and alternatives to address short-term cash needs and access to capital is necessary to progress development of SB206. Since the report of 2022 results in late March, Novan held an analyst and investor day and announced a publication supportive of patient use of Wynzora.
Highlights for 2023 include:
SB206 NDA submitted for molluscum contagiosum January 2023
NDA accepted for SB206 assigning 5JAN24 PDUFA date March 2023
$6 million registered direct offering March 2023
Investor KOL event with Dr. Sugarman on molluscum unmet need April 2023
Publication of survey on patient needs for psoriasis medication April 2023
With respect to financial performance, Novan generated $3.2 million in 1Q:23 revenues versus $1.9 million in 1Q:22, and posted a net loss of ($14.1) million or ($0.54) per share compared to a loss of ($13.4) million or ($0.71) per share in the prior year period.
For the quarter ending March 31, 2023 and versus the same prior year period:
Revenues were $3.2 million, up 64% from $1.9 million. The increase is predominantly due to revenue contribution from sales of dermatology products Wynzora, Rhofade, Minolira and Cloderm and recognition of a full quarter of sales in 1Q:23 compared with 20 days of sales in 1Q:22. Year over year increases were tempered by Rhofade suffering a manufacturing delay which led to a to lack of inventory and loss of sales in 1Q:23; however, management noted that a rebound in orders was experienced in the second quarter as units were restocked. Furthermore, deductible resets for 2023 contributed to the sequential slowdown in scripts and revenues for Novans three leading products.
Story continues
License and collaboration revenues of $585,000 were down 50% due to the absence of revenues from the distribution and supply agreement for Cloderm. Research and grant revenues were up 370% to $170,000 from $36,000 on recognition of multiple federal grants;
Cost of goods sold was $1.3 million vs. $0.2 million;
Research & development expenses totaled $4.8 million, essentially flat with prior year levels. Declines in spending on the SB206 program were offset by increases in other research and development expenses related to a $1 million milestone payment to Ligand;
Selling, general & administrative expenses were $10.0 million, also flat with prior year amounts. 1Q:22 expenses related to the EPI acquisition were replaced by greater commercialization spending for the product portfolio in 1Q:23;
Net loss was ($14.1) million, or ($0.54) per basic and diluted share, compared to ($13.4) million, or ($0.71) per share.
As of March 31, 2023, cash and equivalents on the balance sheet totaled $12.5 million. This compares to cash holdings of $12.3 million at the end of 2022. Cash burn was ($4.3) million which was partially offset by $4.1 million of net contributions from financing. $6.0 million of this amount was from the direct offering which was executed in mid-March. $5.0 million was also received from Sato related to the license agreement for Rhofade. $1.25 million of the Sato/Rhofade upfront is owed to a third party tempering the impact from this cash flow. Novan anticipates that there is sufficient liquidity to support operations until late second quarter 2023.
Corporate Updates
Psoriasis Publication
Findings from a National Psoriasis Foundation study were published in the Journal of Drugs in Dermatology which surveyed more than 400 US patients on patient adherence to topical psoriasis medications. The title of the April 2023 publication is Patient Preferences in Topical Psoriasis Treatment by Curcio, et al.1 The 17-question survey was administered in March 2022 and queried participants on psoriasis severity, bothersome signs and symptoms, current treatment modalities, frequency of topical therapy use, and vehicle preferences.
84% of the participants reported moderate psoriasis with 72.5% of participants using oral medication and 8% topical treatment alone. 76% used topical therapy at least once weekly and 80% reported that they would wait two weeks after starting a new topical treatment before considering discontinuation. Participants preferred water-based creams (75.7%), followed by oil-based foam (70.8%), gel (48.7%), solution (42.8%), lotion (21.2%), non-oil-based foam (17.5%), ointment (16.5%), and spray (6.3%). Other desirable features were formulas that did not stain, were absorbed quickly, were not sticky and were easy to apply. 75% said they would continue to use a psoriasis medication for a week before stopping if they didnt like its topical formulation.
Novans press release continued with a summary of Wynzoras features. Novans product, which is commercialized jointly with MC2 Therapeutics, offers a rapid onset of action with results seen in efficacy, scale and itch as early as one week after application and continued improvement at 8 weeks. Additional detail on Wynzoras profile are included in an analysis by Han, et al.2 and in the products label.
A Discussion of Molluscums Unmet Need
Novan held a stakeholder event on April 25th, 2023 featuring pediatric dermatologist Jeffrey Sugarman, MD, PhD to discuss molluscums unmet need with investors and analysts. The presentation began with an introduction by CEO Paula Brown Stafford who summarized the companys pipeline and the status of lead candidate SB-206, which is now being considered for approval by the FDA. She was followed by Chief Commercial Officer Brian Johnson who quantified the unmet need for molluscum patients. Existing options for patients include potentially painful in-office procedures and non-approved approaches that have limited efficacy. Health care providers (HCPs) want to see solutions for MC and are willing to prescribe an effective medicine if available.
To provide the HCP perspective, pediatric dermatologist Dr. Jeffrey Sugarman was featured who also served as the safety monitor for the Phase III clinical trials for SB-206. MC is commonly seen in children from 3 to 8 years of age, but does move outside of this range. Children with MC frequently also experience eczema, which can make the disease uncomfortable in addition to unsightly and contagious. Dr. Sugarman identified some of the features that physicians would like to see in an MC treatment. These include a safe, effective and well-tolerated product that is convenient to use. SB-206 achieves these objectives for patients, including convenience as it is a prescribed product that can be used at home.
Further discussion detailed the manufacturing and commercialization activities that have been taking place and that will take place over the next quarters. Pediatric dermatologists and primary care pediatricians will be the target audience for the anticipated marketing effort. The panel participants brought up the pending target action date for Verricas cantharidin treatment for MC which is in late July. Having two companies commercializing simultaneously could be beneficial for educating providers on the available options.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
________________________
1. Curcio, A., et al. Patient Preferences in Topical Psoriasis Treatment. Journal of Drugs in Dermatology, April 2023.
2. Han, G., Feldman, S., Bhatia, N., & Prstegaard, M. (2022). Dipropionate (Bdp) Cream (Cal 0.005%/Bdp 0.064% W/W) Improves Plaque Psoriasis At Week One In A Phase 3 Trial. SKIN The Journal of Cutaneous Medicine, 6(4), s42. https://doi.org/10.25251/skin.6.supp.42
Continue reading here:
NOVN: Counting Down to PDUFA - Yahoo Finance
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]
- Woman, 29, Slams Bullies Who 'Giggle And Whisper' At Her Unsightly Psoriasis Sores And Scabs, Leaving Her Depressed And 'Struggling To Walk' -... - August 15th, 2022 [August 15th, 2022]